Abstract: FR-PO634
A Comparison of the Effect of Sodium Bicarbonate on Acid-Base Indices in CKD Patients with and Without Diabetes: A Secondary Analysis of the BASE Pilot Trial
Session Information
- Fluid and Electrolytes: Clinical - Acid-Base, Magnesium, Calcium, Phosphorus
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Fluid and Electrolytes
- 902 Fluid and Electrolytes: Clinical
Authors
- Raphael, Kalani L., University of Utah, Salt Lake City, Utah, United States
- Larive, Brett, Cleveland Clinic, Cleveland, Ohio, United States
- Isakova, Tamara, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
- Ix, Joachim H., UCSD, San Diego, California, United States
- Wolf, Myles, Duke University, Durham, North Carolina, United States
- Raj, Dominic S., GWU Medical Faculty Associates, Washington, District of Columbia, United States
- Mendley, Susan R., NIDDK/NIH, Bethesda, Maryland, United States
- Fried, Linda F., VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
- Kendrick, Cynthia A., Cleveland Clinic, Cleveland, Ohio, United States
- Gassman, Jennifer J., Cleveland Clinic, Cleveland, Ohio, United States
- Cheung, Alfred K., University of Utah, Salt Lake City, Utah, United States
Group or Team Name
- The CKD Pilot Studies Consortium
Background
In CKD, those with diabetes mellitus (DM) tend to have higher urinary NH4+ (u-NH4+) excretion, lower urinary pH (u-pH), and in some studies, higher serum total CO2 (s-tCO2) than those without DM at the same level of eGFR. The comparative effect of NaHCO3 supplementation on acid-base indices in those with and without DM is uncertain.
Methods
This was a secondary analysis from the Bicarbonate Administration to Stabilize eGFR (BASE) Pilot Trial, which was a randomized, double-blinded, placebo-controlled study to determine the safety and tolerability of two doses of NaHCO3 in 194 CKD patients over 28 weeks. 90 participants received higher dose NaHCO3 (0.8 meq/kg-lean/d), 52 received lower dose NaHCO3 (0.5 meq/kg-lean/d; n=52), and 52 received placebo. The BASE Pilot Trial found that both doses were safe and well tolerated (Kidney Week 2018, SA-OR036). In this study, we compared the mean change in u-NH4+ excretion, u-pH, and s-tCO2 from baseline between the treatment groups, stratified by DM status, using linear mixed models adjusted for demographics, eGFR, ACR, diuretic use, ACE/ARB use, protein intake, and clinical center.
Results
Mean±SD age was 67±12 years and eGFR was 36±9 ml/min/1.73m2; 54% had diabetes. In DM vs. non-DM, baseline s-tCO2 was 24±2 vs. 24±3 meq/L (p=0.95); u-NH4+ was 22±14 vs. 20±10 meq/d (p=0.19), and u-pH was 5.7±0.5 vs 5.9±0.5 (p=0.03). The lower dose reduced u-NH4+ excretion and increased u-pH similarly in non-DM and DM (Table). With the higher dose, additional effects on u-NH4+ excretion and u-pH were more robust in non-DM, however the interaction p-values were not significant. In both DM and non-DM, statistically significant increases in s-tCO2 were only observed in those treated with the higher NaHCO3 dose.
Conclusion
In individuals with CKD, NaHCO3 may have an attenuated dose-response effect on urinary acid excretion in DM. However, the effect of NaHCO3 on s-tCO2 seems to be similar for those with and without DM, and only the higher dose significantly increased s-tCO2
Measurement | Urinary NH4+ (% change) | Urinary pH | Serum total CO2 (meq/L) | ||||||
Comparison | Non-DM | DM | p- interaction | Non-DM | DM | p- interaction | Non-DM | DM | p- interaction |
Lower dose vs. placebo | -28% (-48% to 0%) | -39% (-57% to -15%) | 0.47 | 0.5 (0.1 to 0.8) | 0.5 (0.2 to 0.9) | 0.77 | -0.3 (-1.5 to 0.9) | 0.6 (-0.7 to 1.9) | 0.31 |
Higher dose vs. placebo | -56% (-68% to -40%) | -46% (-60% to -27%) | 0.34 | 0.9 (0.6 to 1.2) | 0.6 (0.3 to 0.9) | 0.27 | 1.2 (0.1 to 2.4) | 1.6 (0.5 to 2.8) | 0.64 |
Higher dose vs. Lower dose | -40% (-56% to -17%) | -11% (-33% to 19%) | 0.07 | 0.4 (0.1 to 0.7) | 0.1 (-0.2 to 0.4) | 0.14 | 1.5 (0.3 to 2.8) | 1.0 (-0.1 to 2.1) | 0.54 |
Funding
- NIDDK Support